hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06263153 id: OSU-23329 id: NCI-2024-00002 type: REGISTRY domain: CTRP (Clinical Trial Reporting Program) briefTitle: Futibatinib in Combination With Durvalumab Prior to Cystectomy for the Treatment of Muscle-Invasive Bladder Cancer Patients Who Are Ineligible for Cisplatin-based Therapy overallStatus: NOT_YET_RECRUITING date: 2024-04-01 date: 2025-12-31 date: 2025-12-31 date: 2024-02-16 date: 2024-03-13 name: Yuanquan Yang class: OTHER name: Gateway for Cancer Research briefSummary: This phase II trial tests how well the combination of futibatinib and durvalumab given before cystectomy works in treating patients with muscle-invasive bladder cancer (MIBC) who are ineligible for cisplatin-based therapy. Cisplatin-based therapy is the standard of care for patients with MIBC. However, many patients cannot receive standard therapy due to poor renal function, peripheral neuropathy, poor functional status, or clinically significant heart failure. Futibatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Durvalumab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. Radical cystectomy is a surgery to remove all of the bladder as well as nearby tissues and organs. Giving futibatinib in combination with durvalumab before surgery may be an effective treatment option for patients with MIBC who are ineligible for cisplatin-based therapy. conditions: Bladder Urothelial Carcinoma conditions: Muscle Invasive Bladder Carcinoma conditions: Stage II Bladder Cancer AJCC v8 conditions: Stage IIIA Bladder Cancer AJCC v8 studyType: INTERVENTIONAL phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 24 type: ESTIMATED name: Biospecimen Collection name: Computed Tomography name: Durvalumab name: Futibatinib name: Magnetic Resonance Imaging name: Radical Cystectomy measure: Complete pathologic response rate measure: Incidence of adverse events (AEs) measure: Pathologic down-staging rate to non-muscle invasive disease measure: Overall survival measure: Progression free survival measure: Frequency and severity of adverse events, including delay in cystectomy sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Ohio State University Comprehensive Cancer Center city: Columbus state: Ohio zip: 43210 country: United States name: Yuanquan Yang, MD, PhD role: CONTACT phone: 614-366-2485 email: Yuanquan.Yang@osumc.edu name: Yuanquan Yang, MD, PhD role: PRINCIPAL_INVESTIGATOR lat: 39.96118 lon: -82.99879 hasResults: False
nctId: NCT06263140 id: Chula-ARC 001/21 briefTitle: Vitamin D Levels in Non-immediate Drug Hypersensitivity Case-control Study overallStatus: COMPLETED date: 2021-05-30 date: 2022-01-15 date: 2022-02-01 date: 2024-02-16 date: 2024-02-16 name: Chulalongkorn University class: OTHER briefSummary: Serum vitamin D levels in drug-induced non-immediate reactions conditions: Stevens-Johnson Syndrome conditions: Drug Reaction With Eosinophilia and Systemic Symptom conditions: Maculopapular Exanthem conditions: Vitamin D Deficiency conditions: Drug-Induced Rash studyType: OBSERVATIONAL observationalModel: CASE_CONTROL timePerspective: PROSPECTIVE count: 120 type: ACTUAL measure: Serum vitamin D levels sex: ALL minimumAge: 15 Years stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: Faculty of Medicine, Chulalongkorn University city: Bangkok zip: 10330 country: Thailand lat: 13.75398 lon: 100.50144 hasResults: False
nctId: NCT06263127 id: CMUH112-REC2-104 briefTitle: Sensory Motor Interventions on Preterm Infants overallStatus: NOT_YET_RECRUITING date: 2024-02-20 date: 2026-01-10 date: 2026-01-10 date: 2024-02-16 date: 2024-02-16 name: China Medical University Hospital class: OTHER briefSummary: Preterm infants experiencing bottle feeding difficulties will be included in this study. Two distinct interventions, oral stimulation (OS) and infant massage (IM), will be administered in this study. The objective of this clinical trial is to compare the effectiveness of these two approaches, either individually or in combination, in improving the feeding performance and development of participants. conditions: Preterm Infants studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: TRIPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: OUTCOMES_ASSESSOR count: 80 type: ESTIMATED name: oral stimulation name: infants massage measure: Oral intake measure: Transition time of oral feeding measure: weight gain measure: Hospital stay measure: Neonatal Neurobehavioral Examination-Chinese Version(NNE-C) measure: Infant/Toddler Sensory Profile-Chinese Version(ITSP-C) measure: Premature Bottle Feeding Questionnaire(PBFQ) sex: ALL maximumAge: 34 Weeks stdAges: CHILD facility: China Medical University Hospital city: Taichung zip: 404 country: Taiwan name: Yu-Rou Chiang, Bachelor role: CONTACT phone: 0910-897-089 email: y198473@gmail.com name: Pei-Yu Yang, Master role: CONTACT phone: 0975-681-610 email: Yangpy888@gmail.com name: Pei-Yu Yang, Master role: PRINCIPAL_INVESTIGATOR name: Yea-Shwu Hwang, ScD role: SUB_INVESTIGATOR lat: 24.1469 lon: 120.6839 hasResults: False
nctId: NCT06263114 id: 00002826 briefTitle: Correlation of Blood Gene Expression (TruGraf Liver) With Liver Biopsy in Pediatric Liver Transplant Recipients overallStatus: RECRUITING date: 2024-01-01 date: 2026-01-01 date: 2027-01-01 date: 2024-02-16 date: 2024-02-16 name: Children's Mercy Hospital Kansas City class: OTHER name: Eurofins briefSummary: Liver transplant rejection is when the body's immune system attacks and damages the liver of a transplant recipient. Currently the best way to see if that is happening is with a liver biopsy. The purpose of this research study is to see if a simple blood test can diagnose if a transplanted liver is being rejected. conditions: Liver Transplant; Complications conditions: Liver Failure, Acute studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 25 type: ESTIMATED name: TruGraf® Liver gene expression panel (GEP) measure: Correlation of the TruGraf® Liver GEP with rejection activity index (RAI) on surveillance and for-cause biopsy. measure: Comparison of the GEP to non-rejection injury found on biopsy measure: Utility of the GEP for monitoring liver injury sex: ALL minimumAge: 1 Year maximumAge: 17 Years stdAges: CHILD facility: Children's Mercy Hospitals and Clinics status: RECRUITING city: Kansas City state: Missouri zip: 64108 country: United States name: Corey Schurman, MA role: CONTACT phone: 816-802-1167 email: crschurman@cmh.edu name: Amber Bagherian, MD role: CONTACT phone: 816-234-3016 name: Ryan Fischer, MD role: PRINCIPAL_INVESTIGATOR lat: 39.09973 lon: -94.57857 typeAbbrev: Prot hasProtocol: True hasSap: False hasIcf: False label: Study Protocol date: 2023-01-03 uploadDate: 2024-01-08T15:14 filename: Prot_000.pdf size: 353012 typeAbbrev: ICF hasProtocol: False hasSap: False hasIcf: True label: Informed Consent Form date: 2023-10-23 uploadDate: 2024-02-14T12:08 filename: ICF_001.pdf size: 244224 hasResults: False
nctId: NCT06263101 id: ChaoyangHospital briefTitle: Drainage Fluid Biomarkers and Postoperative Gastrointestinal Dysfunction in Laparoscopic Colorectal Surgery overallStatus: RECRUITING date: 2024-02-21 date: 2024-10-01 date: 2024-10-01 date: 2024-02-16 date: 2024-04-10 name: Chaoyang Hospital of China Medical University class: OTHER_GOV briefSummary: Postoperative gastrointestinal dysfunction (POGD), often referred to as postoperative ileus (POI) after colorectal surgery, is characterized by symptoms such as nausea, vomiting, abdominal distension, and delayed bowel movements. The incidence of this issue varies among medical institutions, impacting patient nutrition, prolonging hospital stays, and increasing healthcare costs.
The complex pathogenesis of POGD involves a brief neurogenic phase (within 3 hours) and a more prolonged inflammatory phase (beginning at 3-4 hours and lasting for days). The inflammatory phase is crucial and is recognized as initiated by mast cells and damage-associated molecular patterns that activate macrophages in the intestinal muscle layer. Subsequently, it triggers a series of cascading inflammation reactions through the release of inflammatory factors and recruitment of inflammatory cells, which contributes to the development and exacerbation of POGD. Studies have demonstrated changes in inflammatory cells and factors in the abdominal fluid following abdominal surgery, emphasizing the clinical significance of analyzing drainage fluid to predict postoperative gastrointestinal function.
This study analyzes inflammatory markers in drainage fluid following laparoscopic colorectal cancer surgery. The aim is to enhance the accuracy of predicting gastrointestinal recovery outcomes and contribute to the evolving field of Enhanced Recovery After Surgery (ERAS). conditions: Postoperative Gastrointestinal Dysfunction (POGD) studyType: OBSERVATIONAL observationalModel: CASE_ONLY timePerspective: PROSPECTIVE count: 63 type: ESTIMATED name: Biochemical testing of abdominal drainage fluid name: Cytological examination of abdominal drainage fluid name: Peripheral blood cytology tests measure: Measurement of drainage fluid LDH and neutrophil to lymphocyte ratio (NLR) on postoperative day 1 measure: Measurement of drainage fluid LDH and neutrophil to lymphocyte ratio (NLR) on postoperative day 3 measure: Measurement of drainage fluid albumin, adenosine deaminase (ADA), lymphocyte-monocyte ratio (LMR), prognostic nutritional index (PNI) on postoperative day 1 measure: Measurement of drainage fluid albumin, adenosine deaminase (ADA), lymphocyte-monocyte ratio (LMR), prognostic nutritional index (PNI) on postoperative day 3 measure: Measurement of blood serum neutrophil-lymphocyte ratio (NLR), lymphocyte-monocyte ratio (LMR), platelet-lymphocyte ratio (PLR), systemic immune-inflammatory index (SII) on postoperative day 1. measure: Measurement of blood serum neutrophil-lymphocyte ratio (NLR), lymphocyte-monocyte ratio (LMR), platelet-lymphocyte ratio (PLR), systemic immune-inflammatory index (SII) on postoperative day 3. sex: ALL minimumAge: 18 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Chaoyang Central Hospital of China Medical University status: RECRUITING city: Chaoyang state: Liaoning country: China name: Xinao Fu role: CONTACT phone: +8618238692250 email: ailun10211@163.com lat: 41.57028 lon: 120.45861 typeAbbrev: Prot hasProtocol: True hasSap: False hasIcf: False label: Study Protocol date: 2024-01-08 uploadDate: 2024-02-12T01:53 filename: Prot_000.pdf size: 182027 typeAbbrev: SAP hasProtocol: False hasSap: True hasIcf: False label: Statistical Analysis Plan date: 2024-01-08 uploadDate: 2024-02-12T01:52 filename: SAP_001.pdf size: 154895 typeAbbrev: ICF hasProtocol: False hasSap: False hasIcf: True label: Informed Consent Form date: 2024-01-08 uploadDate: 2024-02-12T01:37 filename: ICF_002.pdf size: 277845 hasResults: False
nctId: NCT06263088 id: CASE15223 briefTitle: EQUITY GI: A Prospective Study to Enhance Quality, Inclusivity, and Trial Participation in Black Patients With Gastrointestinal Cancer. overallStatus: NOT_YET_RECRUITING date: 2024-07 date: 2026-06-30 date: 2026-06-30 date: 2024-02-16 date: 2024-02-20 name: Case Comprehensive Cancer Center class: OTHER briefSummary: This research study is being conducted to improve the quality of care of participants who have a diagnosis of gastrointestinal cancer (anal, colon, rectal, esophageal, stomach, small bowel, appendix, pancreas, gall bladder, liver, neuroendocrine tumor of gastrointestinal origin).
1. Ensuring appropriate biomarker testing and evidence-based care: Biomarkers are molecules in the tumor or blood that indicate normal or abnormal processes in participant's body and may indicate an underlying condition or disease. Various molecules, such as DNA (genes), proteins, or hormones, can serve as biomarkers since they all indicate something about participant's health. Biomarker testing can also help choose participant's treatment. Additionally, a tumor board will be conducted periodically to provide treatment recommendations to participant's treating physician. Participants will receive standard-of-care treatment if participant enroll in this study. Participant will not receive any experimental treatment.
3. Health literacy: The study team will provide information relevant to participant's diagnosis to enrich participant's understanding of participant's condition and treatment. Investigator will provide questionnaires to assess participant's understanding before and after participant's have been provided with educational/informational material appropriate for participant's diagnosis. conditions: Gastrointestinal Cancer conditions: Colon Cancer conditions: Rectal Cancer conditions: Anal Cancer conditions: Esophageal Cancer conditions: Stomach Cancer conditions: Appendix Cancer conditions: Pancreas Cancer conditions: Liver Cancer conditions: Neuroendocrine Tumors studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: Single arm study to address the existing disparities faced by Black participants with gastrointestinal (GI) cancer in accessing crucial biomarker testing, receiving evidence-based care, and participating in clinical trials. primaryPurpose: SUPPORTIVE_CARE masking: NONE count: 200 type: ESTIMATED name: EQUITY GI measure: Biomarker testing rate of Black participants diagnosed with GI cancer measure: Clinical trial enrollment rate among black participants diagnosed with GI cancer measure: Change in Health literacy test among black participants diagnosed with GI cancer measure: Change in Health literacy score among black participants diagnosed with GI cancer sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University Hospitals Cleveland Medical Center, Seidman Cancer Center, Case Comprehensive Cancer Center city: Cleveland state: Ohio zip: 44106 country: United States name: Sakti Chakrabarti, MD role: CONTACT phone: 216-844-3951 email: sakti.chakrabarti@uhhospitals.org lat: 41.4995 lon: -81.69541 hasResults: False
nctId: NCT06263075 id: 717/2023/Oss/AOUBo id: 6822 type: OTHER domain: SirER (Emilia-Romagna Research Information System) platform briefTitle: Hemodynamic Monitoring During Craniosynostosis Surgery: Comparing Traditional and Newer Technology Monitors (CRASY-PRAM) acronym: CRASY-PRAM overallStatus: RECRUITING date: 2023-12-13 date: 2025-12 date: 2026-06 date: 2024-02-16 date: 2024-02-16 name: IRCCS Azienda Ospedaliero-Universitaria di Bologna class: OTHER briefSummary: Hemodynamic evaluation during pediatric anesthesia is essential to care management. Intraoperative cardiovascular instability is frequent in major surgeries, and appropriate monitoring is necessary to ensure safe anesthetic conduction and promptly detect changes in blood pressure, cardiac output, blood volume, and organ perfusion. In this context, advanced hemodynamic monitoring, continuous measuring, and estimating various parameters can allow a more specific hemodynamic profile and help identify the causal mechanisms of its variability. Moreover, the reference ranges of hemodynamic values in different pediatric ages and how to best monitor hemodynamic status in pediatrics are still debated.
This study aims to characterize the hemodynamic events occurring during corrective craniosynostosis surgery, recorded simultaneously with standard monitoring and Pressure Recording Analytic Method (PRAM), and to analyze the paired measurements. conditions: Craniosynostoses conditions: Hypovolemia conditions: Hemorrhage conditions: Hemodynamic Instability studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 30 type: ESTIMATED name: Intraoperative monitoring measure: Hemodynamic events occurring during surgery measure: Evaluation of changes in volemic status measure: Evaluation of changes in volemic status measure: Evaluation of changes in systemic vascular resistance measure: Evaluation of changes in cardiac function measure: Evaluation of changes in cardiac function sex: ALL minimumAge: 3 Months maximumAge: 8 Months stdAges: CHILD facility: IRCCS AOU of Bologna Policlinico Sant'Orsola status: RECRUITING city: Bologna state: BO zip: 40138 country: Italy name: Luigia Scudeller, MD role: CONTACT phone: 051 2141402 phoneExt: +39 email: luigia.scudeller@aosp.bo.it name: Barbara Lotito, MD role: CONTACT phone: 051 2141296 phoneExt: +39 email: barbara.lotito@aosp.bo.it name: Lorena Pasini, MD role: SUB_INVESTIGATOR name: Fabio Caramelli, MD role: SUB_INVESTIGATOR name: Rosario Ruga, Student role: SUB_INVESTIGATOR name: Andrea La Placa, MD role: SUB_INVESTIGATOR lat: 44.49381 lon: 11.33875 hasResults: False
nctId: NCT06263062 id: women undergoing colposcopy briefTitle: Management With Fear of Cancer in Women Undergoing Colposcopy: Randomized Controlled Study overallStatus: RECRUITING date: 2021-01-07 date: 2024-06-15 date: 2024-06-15 date: 2024-02-16 date: 2024-02-16 name: Alanya Alaaddin Keykubat University class: OTHER briefSummary: Cervical cancer is the fourth most common cancer in women worldwide. Due to advances in early diagnosis and treatment, the number of survivors of cancer has increased over the past 50 years. Therefore, the current standard of care for the detection of cervical neoplasm, a Papanicolaou smear and then a colposcopic biopsy, requires a high degree of diagnostic accuracy. In particular, the fear of developing cancer after cancer screening tests is becoming an increasingly significant problem, with an impact on psychosocial health in individuals. For people who are afraid of cancer, meditation and awareness training can make it easier for emotions to self-regulate in times of distress and pain. This study aim to conducted to determine the impact of the Awareness-Based Initiation Program on cancer fear and level of awareness in women undergoing colonoscopy. conditions: Cancer Fear conditions: Cervical Cancer studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: SUPPORTIVE_CARE masking: DOUBLE whoMasked: PARTICIPANT whoMasked: OUTCOMES_ASSESSOR count: 60 type: ESTIMATED name: Awareness-Based Coping with Fear of Cancer Programme measure: The Cancer Worry Scale measure: Philadelphia Mindfulness Scale sex: FEMALE minimumAge: 18 Years maximumAge: 70 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Alanya Alaaddin Keykubat University status: RECRUITING city: Alanya zip: 7400 country: Turkey name: fatma ozlem uner, MSc role: CONTACT phone: +905062972749 email: fatma.uner@alanya.edu.tr lat: 36.54375 lon: 31.99982 hasResults: False
nctId: NCT06263049 id: ejaculation post TURP briefTitle: Is Ejaculation Preservation TURis the Natural Evolution of the "Gold Standard". overallStatus: COMPLETED date: 2023-05-01 date: 2024-01-01 date: 2024-02-01 date: 2024-02-16 date: 2024-04-24 name: Ain Shams University class: OTHER briefSummary: evaluation of the impact of apical urethral mucosa sparring with the urethra around the verumontanum on the ejaculatory function and early postoperative urinary incontinence conditions: Benign Prostatic Hyperplasia studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: PREVENTION masking: NONE count: 106 type: ACTUAL name: transurethral resection of prostate measure: post operative antegrade ejaculation measure: post operative urine continence sex: MALE minimumAge: 40 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Ain shams university city: Cairo country: Egypt lat: 30.06263 lon: 31.24967 hasResults: False
nctId: NCT06263036 id: Bilgen S briefTitle: Morphometric Examination of the Larynx overallStatus: COMPLETED date: 2013-01-10 date: 2013-06-10 date: 2013-06-10 date: 2024-02-16 date: 2024-02-16 name: Acibadem University class: OTHER briefSummary: Objective: To measure laryngeal dimensions in a sample of Turkish cadavers including males and females of various ages and heights.
Patients and Methods: Morphological measurement was performed on 102 laryngeal specimens. Laryngeal cartilages were collected from human cadavers. All dimensions of the cartilages were measured using a thread and vernier calipers. Age, sex, and height were recorded. Results for men and women were compared. conditions: Laryngeal Dimensions in Males and Females studyType: OBSERVATIONAL observationalModel: OTHER timePerspective: OTHER count: 102 type: ACTUAL name: Men name: Women measure: To measure laryngeal dimensions in cadavers sex: ALL stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06263023 id: 34L-CP-02-009 briefTitle: A Central Preservation and Assessment Service to Optimize Donor Kidney Allocation acronym: OPTIMAL overallStatus: RECRUITING date: 2024-04-19 date: 2025-03 date: 2025-09 date: 2024-02-16 date: 2024-04-24 name: 34 Lives, PBC class: INDUSTRY name: Indiana University Health name: University of Miami name: MOUNT SINAI HOSPITAL name: University of Wisconsin, Madison briefSummary: This is a study to collect information to assess if transporting hard-to-place (HTP) donor kidneys to a central preservation and assessment facility with dedicated organ assessment capabilities increases allocation success to transplant hospitals. conditions: Organ Preservation studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 80 type: ESTIMATED name: Sub-Normothermic Machine Preservation and Assessment measure: Transplant Allocation Success measure: 7-Day Delayed Graft Function (DGF) measure: Graft Survival measure: Patient Survival measure: Serum Creatinine (sCr) measure: eGFR measure: Long term data collection- Graft Survival measure: Long term data collection- Patient Survival measure: Long term data collection- Serum Creatinine measure: Long term data collection- eGFR sex: ALL minimumAge: 16 Years maximumAge: 75 Years stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: Miami Transplant Institute, University of Miami Miller School of Medicine status: NOT_YET_RECRUITING city: Miami state: Florida zip: 33136 country: United States name: Giselle Guerra, MD role: CONTACT name: Giselle Guerra, MD role: PRINCIPAL_INVESTIGATOR lat: 25.77427 lon: -80.19366 facility: Indiana University Health status: RECRUITING city: Indianapolis state: Indiana zip: 46202 country: United States name: William Goggins, MD role: CONTACT name: William Goggins, MD role: PRINCIPAL_INVESTIGATOR lat: 39.76838 lon: -86.15804 facility: The Mount Sinai Hospital status: RECRUITING city: New York state: New York zip: 10029 country: United States name: Matthew Holzner, MD role: CONTACT name: Matthew Holzner, MD role: PRINCIPAL_INVESTIGATOR lat: 40.71427 lon: -74.00597 facility: University of Wisconsin School of Medicine and Public Health status: NOT_YET_RECRUITING city: Madison state: Wisconsin zip: 53792 country: United States name: Jacqueline Garonzik Wang, MD role: CONTACT name: Jacqueline Garonzik Wang, MD role: PRINCIPAL_INVESTIGATOR lat: 43.07305 lon: -89.40123 hasResults: False
nctId: NCT06263010 id: CIBS-2023-01 briefTitle: Allopregnanolone as a Regenerative Treatment for Parkinson's Disease acronym: Allo-PD overallStatus: RECRUITING date: 2024-01-12 date: 2024-09 date: 2024-12 date: 2024-02-16 date: 2024-02-20 name: Roberta Brinton class: OTHER briefSummary: The goal of this open-label, pilot clinical trial is to test allopregnanolone as a regenerative treatment in patients with Parkinson's disease (PD). The main questions this study aims to answer are: